Board certified Tampa facial plastic surgeon Michael E. Jasin, MD, FACS will be among the first to gain exclusive access to XEOMIN® in the Tampa Bay area. Merz Aesthetics on July 21, 2011 announced that the United States (U.S.) Food and Drug Administration (FDA) has approved XEOMIN® (incobotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.
Tampa, FL (December 2011) – At his Tampa, FL plastic surgery practice, Dr. Michael E. Jasin is announcing the addition of a new facial rejuvenation procedure known as XEOMIN. He says he is very excited to be able to offer his patients this procedure following the success of the FDA approval process. Dennis Condon, President and Chief Business Officer of Merz Aesthetics, Inc., had this to say about the approval: “The FDA approval of XEOMIN is a significant milestone for Merz Aesthetics and a promising addition to our entire aesthetics franchise. We are confident that XEOMIN will provide patients and physicians with a new option for improving the appearance of glabellar lines.”
“XEOMIN is a promising new option for both patients and physicians and we are encouraged by the response rates seen in the Phase III clinical trials,” said Derek H. Jones, M.D., an investigator for the XEOMIN U.S. study, Clinical Associate Professor of Medicine at the University of California in Los Angeles, Calif., and Director of Skin Care and Laser Physicians in Beverly Hills, Calif.
The approval of XEOMIN is based on the results of two pivotal U.S. clinical trials involving 16 investigational sites and included 547 healthy adult patients. In both studies, XEOMIN significantly improved the appearance of glabellar lines 30 days following the first injection, when compared to placebo. XEOMIN is the only botulinum toxin currently approved in the U.S. that does not require refrigeration prior to reconstitution.
XEOMIN is approved for the temporary improvement in the appearance of glabellar lines in 14 countries in the European Union (EU), including Germany, the United Kingdom, France, Italy and Spain, under the brand name BOCOUTURE®.
XEOMIN will be available nationwide to physicians in the spring of 2012, but is available now at The Elite Facial Plastic Surgery. In addition, because of his expertise Dr. Jasin is the only doctor in the Tampa Bay Area chosen to be a part of the XEOMIN Medical Advisory Board. Dr. Jasin says XEOMIN differs from BOTOX® Cosmetic because it lacks proteins that may induce antibodies that can lessen its effectiveness. “XEOMIN represents an FDA approved alternative to BOTOX® which is less expensive yet equally effective for reduction of facial lines and wrinkles and control of excessive sweating.”
About Michael E. Jasin, MD, FACS
Raised in Tampa, Michael E. Jasin, M.D. graduated from the University of South Florida College of Medicine in 1978. After graduating, he served at General Surgery Internship at USF and a Residency in Otolaryngology – Head and Neck Surgery and Facial Plastic Surgery at the Medical University of South Carolina. The Elite Facial Plastic Surgery was opened in 1982. He is a fellow of the American Academy of Facial Plastic and Reconstructive Surgery, American College of Surgeons, and American Academy of Otolaryngology – Head and Neck Surgery. He serves on the National Education Faculty for BOTOX® and Radiesse. Being a recognized leader in his field, Dr. Jasin participates in clinical studies and sits on various advisory boards. Dr. Jasin has held several medical staff offices at University Community Hospital. The Elite Facial Plastic Surgery is a AAAHC Fully Accredited Facility and also serves as a training site for physicians from all over the world to learn various laser and injectable filler techniques.
The Elite Facial Plastic Surgery is located at 13801 Bruce B. Downs Blvd. Suite 305, Tampa, FL 33606, and can be reached at 813-975-3223 or (888) 975-3223. The practice can also be reached through email at firstname.lastname@example.org and found online at www.jasinfacial.com.